Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Dr. Leonard S. Schleifer M.D., Ph.D.

Co-Founder, President, Chief Executive Officer & Co-Chairman

Dr. Andrew J. Murphy Ph.D.

Executive Vice President of Research

Mr. Daniel P. Van Plew

Executive Vice President and GM of Industrial Operations & Product Supply

Mr. Christopher R. Fenimore CPA

Senior Vice President of Finance & Chief Financial Officer

Mr. Ryan  Crowe

Senior Vice President of Investor Relations & Strategic Analysis

Ms. Melissa  Lozner

Senior Vice President & Chief Compliance Officer

Dr. George D. Yancopoulos M.D., Ph.D.

Co-Founder, President, Chief Scientific Officer & Co-Chairman

Ms. Patrice  Gilooly

Senior Vice President of Quality Assurance & Operations

Mr. Bob  McCowan

Senior Vice President of IT & Chief Information Officer

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel & Secretary

Biotechnologie

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. Struktura vedení

Informace o vedení